Small Intestinal Mucosal Breaks with Short-Term Administration of Non-Steroidal Anti-Inflammatory Drugs

2008 ◽  
Vol 67 (5) ◽  
pp. AB271-AB272
Author(s):  
Katya Gudis ◽  
Shunji Fujimori ◽  
Yukie Yamada ◽  
Yoko Takahashi ◽  
Tsuguhiko Seo ◽  
...  
2009 ◽  
Vol 69 (5) ◽  
pp. AB100
Author(s):  
Shunji Fujimori ◽  
Katya Gudis ◽  
Yoko Takahashi ◽  
Tsuguhiko Seo ◽  
Akihito Ehara ◽  
...  

2021 ◽  
Vol 38 (9) ◽  
pp. 1003-1005
Author(s):  
Sara Thietart ◽  
Margaux Baque ◽  
Judith Cohen-Bittan ◽  
Mathieu Raux ◽  
Bruno Riou ◽  
...  

2009 ◽  
Vol 12 (11) ◽  
pp. 1113-1121 ◽  
Author(s):  
Tomoyoshi Shibuya ◽  
Toshifumi Ohkusa ◽  
Tetsuji Yokoyama ◽  
Akira Harada ◽  
Kazuko Beppu ◽  
...  

2019 ◽  
Vol 47 (6) ◽  
pp. 559-567 ◽  
Author(s):  
A. E. Karateev ◽  
E. V. Moroz ◽  
E. V. Kryukov

The use of nonsteroidal anti-inflammatory drugs (NSAID), even if short-term, may be associated to small intestinal complications, such as erosions, ulcers and chronic mucosal inflammation. Video capsule endoscopy allows for identification of such lesions in 20 to 55% of the patients who have taken nonselective NSAID for 2 to 4  weeks. The pathophysiology of NSAID-induced enteropathy is related to a reduced reparative potential of the mucosa and abnormalities of the microbial balance in the small intestine. In real world practice, NSAID enteropathy is commonly asymptomatic, and its manifestations, such as bleeding, perforation and ileus, are quite rare (about 0.3 episodes per 100  patient-years). The main manifestation of NSAID enteropathy is chronic iron deficient anemia. The use of rebamipide, sulfasalazine, mesalazine, and rifaximin has been discussed in the treatment of NSAID enteropathy, whereas its prevention implies preferential administration of coxibs, the use of rebamipide and probiotics.


2007 ◽  
Vol 24 ◽  
pp. 88-95 ◽  
Author(s):  
T. OHKUSA ◽  
T. TERAI ◽  
S. ABE ◽  
O. KOBAYASHI ◽  
K. BEPPU ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document